Acumen Pharmaceuticals In... (ABOS)
undefined
undefined%
At close: undefined
2.03
0.00%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease.

The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.

Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc. logo
Country United States
IPO Date Jul 1, 2021
Industry Biotechnology
Sector Healthcare
Employees 51
CEO Daniel J. O'Connell M.B.A.

Contact Details

Address:
427 Park Street
Charlottesville, Virginia
United States
Website https://acumenpharm.com

Stock Details

Ticker Symbol ABOS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001576885
CUSIP Number 00509G209
ISIN Number US00509G2093
Employer ID 36-4108129
SIC Code 2836

Key Executives

Name Position
Daniel J. O'Connell M.B.A. Chief Executive Officer & Director
Derek M. Meisner Esq., J.D. Chief Legal Officer & Corporate Secretary
Matt Zuga Chief Financial Officer & Chief Business Officer
Russell Barton M.S. Chief Operating Officer
Alex Braun M.B.A. Vice President & Head of Investor Relations
Dr. Caleb E. Finch Ph.D. Co-Founder
Dr. Grant A. Krafft Ph.D. Co-Founder
Dr. James Doherty Ph.D. President & Chief Development Officer
Dr. William L. Klein Ph.D. Co-Founder
Kelly Carranza Vice President, Finance & Accounting and Corporate Controller

Latest SEC Filings

Date Type Title
Nov 12, 2024 10-Q Quarterly Report
Nov 06, 2024 4 Filing
Nov 06, 2024 3 Filing
Aug 13, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report
Jun 10, 2024 4 Filing
Jun 10, 2024 4 Filing
Jun 10, 2024 4 Filing
Jun 10, 2024 4 Filing
Jun 10, 2024 4 Filing